Innovation
New Antimicrobial Drugs: EU Policy Options
4 October 2010
Antimicrobial resistance to drugs is a growing global public health issue. The EU began a discussion in 2009 about which policies can best encourage the development…
Value Based Pricing in the UK
7 September 2010
Every country around the globe struggles with attaining an appropriate balance between providing affordable health care and ensuring access to medical advances. In a recent article…
Defining Benefit Through Willingness to Pay
24 August 2010
Since 2007, new medications may be paid for by the statutory health insurance funds (GKV) in Germany only if they are cost-effective. Willingness-to-pay analyses can be…
Biosimilars and Data Exclusivity
8 June 2010
Data exclusivity is critical to ensuring that biosimilars achieve an appropriate balance between increasing market competition and encouraging innovation. The history of ‘traditional generics’ is a…
The Impact of Biosimilars on Markets
24 May 2010
The availability of biosimilars — ‘copies’ of biologics — is very recent and limited so far to only a few products. Projecting the impact on markets…
Evaluating Medical Innovation: The Societal View
8 April 2010
In a recent OHE Briefing, five leading European experts in health economics provide a comprehensive international review of changes in health economic evaluation and the reasons…
Science Policy Research: Having an Impact on Policy?
1 December 2010
Professor Ben Martin (Science and Technology Policy Studies at SPRU, University of Sussex) defines science policy research as ’economic, policy, management and organisational studies of science,…
Assessment of the Impact of Orphan Medicinal Products on the European Economy and Society
1 November 2010
This report examines the effect of the European Union’s 1999 Regulation on Orphan Medicinal Products (OMPs) on the European economy and society. This study collected data…
Innovation in Medicines: Can We Value Progress?
1 August 2010
Summarised in this publication are the main points and conclusions from a discussion facilitated by OHE that focused on innovation in the pharmaceutical industry. Participants included…